Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2ZZ
|
|||
| Former ID |
DCL000525
|
|||
| Drug Name |
Esomeprazole magnesium + Aspirin
|
|||
| Indication | Peptic ulcer [ICD-11: DA61] | Phase 3 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric H(+)/K(+) ATPase alpha (ATP4A) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Oxidative phosphorylation | |||
| Collecting duct acid secretion | ||||
| Gastric acid secretion | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Ion transport by P-type ATPases | |||
| WikiPathways | Iron uptake and transport | |||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90. | |||
| REF 2 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.